CytoMed Therapeutics
GDTC
2 hedge funds and large institutions have $70.3K invested in CytoMed Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
105% more capital invested
Capital invested by funds: $34.3K → $70.3K (+$36K)
100% more funds holding
Funds holding: 1 → 2 (+1)
0.19% more ownership
Funds ownership: 0.09% → 0.27% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$45.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $38.8K | +$45.7K | +17,250 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $31.5K | +$11.5K | +4,349 | +43% |
|
GDTC Hedge Fund Activity: Q1 2025 in Review
2 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q1 2025, worth a combined $70.3K — up 105% from $34.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GDTC positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $45.7K.
- 2 institutional investors held CytoMed Therapeutics (GDTC) as of Q1 2025, up from 1 in Q4 2024.
- Funds reported $70.3K of CytoMed Therapeutics stock for Q1 2025, up 105% quarter-over-quarter.
- 1 fund opened new CytoMed Therapeutics positions in Q1 2025 and 0 closed out, a net change of +1 holder.
- The largest CytoMed Therapeutics buyer in Q1 2025 was Citadel Advisors, an estimated $45.7K added.
Based on aggregated 13F filings for Q1 2025.